367 related articles for article (PubMed ID: 11859652)
1. [Competitive morbidity ant its impact on life expectancy: evaluation and inclusion in the therapeutic decision regarding localized prostatic cancer].
Soulié M; Villers A; Richaud P; Prapotnich D; Ruffion A; Grosclaude P
Prog Urol; 2001 Dec; 11(6):1195-204. PubMed ID: 11859652
[TBL] [Abstract][Full Text] [Related]
2. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
[TBL] [Abstract][Full Text] [Related]
3. [Standards, options and recommendations for the management of prostate cancer: therapeutic decision criteria].
Chatelard PP;
Bull Cancer; 2002 Jun; 89(6):619-34. PubMed ID: 12135863
[TBL] [Abstract][Full Text] [Related]
4. Natural course of localized prostate cancer. a personal view with a review of published papers.
Hugosson J; Aus G
Anticancer Res; 1997; 17(3A):1441-8. PubMed ID: 9179181
[TBL] [Abstract][Full Text] [Related]
5. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.
Shimizu F; Igarashi A; Fukuda T; Kawachi Y; Minowada S; Ohashi Y; Fujime M
Jpn J Clin Oncol; 2007 Oct; 37(10):763-74. PubMed ID: 17956899
[TBL] [Abstract][Full Text] [Related]
6. An analysis of watchful waiting for clinically localized prostate cancer.
Steinberg GD; Bales GT; Brendler CB
J Urol; 1998 May; 159(5):1431-6. PubMed ID: 9554328
[TBL] [Abstract][Full Text] [Related]
7. Do older men benefit from curative therapy of localized prostate cancer?
Alibhai SM; Naglie G; Nam R; Trachtenberg J; Krahn MD
J Clin Oncol; 2003 Sep; 21(17):3318-27. PubMed ID: 12947068
[TBL] [Abstract][Full Text] [Related]
8. The impact of co-morbidity on life expectancy among men with localized prostate cancer.
Albertsen PC; Fryback DG; Storer BE; Kolon TF; Fine J
J Urol; 1996 Jul; 156(1):127-32. PubMed ID: 8648773
[TBL] [Abstract][Full Text] [Related]
9. Results of conservative management of clinically localized prostate cancer.
Chodak GW; Thisted RA; Gerber GS; Johansson JE; Adolfsson J; Jones GW; Chisholm GD; Moskovitz B; Livne PM; Warner J
N Engl J Med; 1994 Jan; 330(4):242-8. PubMed ID: 8272085
[TBL] [Abstract][Full Text] [Related]
10. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer.
Sommers BD; Beard CJ; D'Amico AV; Dahl D; Kaplan I; Richie JP; Zeckhauser RJ
Cancer; 2007 Nov; 110(10):2210-7. PubMed ID: 17893907
[TBL] [Abstract][Full Text] [Related]
11. The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis.
Mold JW; Holtgrave DR; Bisonni RS; Marley DS; Wright RA; Spann SJ
J Fam Pract; 1992 May; 34(5):561-8. PubMed ID: 1578205
[TBL] [Abstract][Full Text] [Related]
12. Predicting life expectancy in men with clinically localized prostate cancer.
Cowen ME; Halasyamani LK; Kattan MW
J Urol; 2006 Jan; 175(1):99-103. PubMed ID: 16406881
[TBL] [Abstract][Full Text] [Related]
13. The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting.
Kastner C; Armitage J; Kimble A; Rawal J; Carter PG; Venn S
Prostate Cancer Prostatic Dis; 2006; 9(3):270-4. PubMed ID: 16770340
[TBL] [Abstract][Full Text] [Related]
14. Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer.
Walz J; Gallina A; Perrotte P; Jeldres C; Trinh QD; Hutterer GC; Traumann M; Ramirez A; Shariat SF; McCormack M; Perreault JP; Bénard F; Valiquette L; Saad F; Karakiewicz PI
BJU Int; 2007 Dec; 100(6):1254-8. PubMed ID: 17979925
[TBL] [Abstract][Full Text] [Related]
15. [Treatment by HIFU of prostate cancer: survey of literature and treatment indications].
Rébillard X; Davin JL; Soulié M;
Prog Urol; 2003 Dec; 13(6):1428-56. PubMed ID: 15000326
[TBL] [Abstract][Full Text] [Related]
16. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
17. Deferred treatment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series.
Adolfsson J; Steineck G; Hedlund PO
Urology; 1997 Nov; 50(5):722-6. PubMed ID: 9372882
[TBL] [Abstract][Full Text] [Related]
18. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
[TBL] [Abstract][Full Text] [Related]
19. Health outcomes in older men with localized prostate cancer: results from the Prostate Cancer Outcomes Study.
Hoffman RM; Barry MJ; Stanford JL; Hamilton AS; Hunt WC; Collins MM
Am J Med; 2006 May; 119(5):418-25. PubMed ID: 16651054
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities.
Tewari A; Johnson CC; Divine G; Crawford ED; Gamito EJ; Demers R; Menon M
J Urol; 2004 Apr; 171(4):1513-9. PubMed ID: 15017210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
